Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer this year in the hemophilia space. Earlier in July, the FDA approved Durveqtix (fidanacogene elaparvovec), the ...

Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...

First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy Beqvez. But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue ...

On Friday, the FDA approved BridgeBio Pharma ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market ...

The FDA has approved Rapiblyk ... Rapiblyk, the brand name for landiolol, is an injectable drug that slows the heart rate by blocking adrenaline's action on beta-1 receptors in the heart.

1 Diagnosed in early childhood, hemophilia inhibits the blood’s ... the FDA at 1-800-FDA-1088. Disclosure notice The information contained in this release is as of November 20, 2024. Pfizer ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...